Welcome to our dedicated page for Inmode news (Ticker: INMD), a resource for investors and traders seeking the latest updates and insights on Inmode stock.
InMode Ltd. reports developments in medical-technology devices that use radiofrequency technology for minimally invasive and non-invasive aesthetic and medical procedures. Company updates commonly address product platforms and treatment categories for plastic surgery, dermatology, gynecology, otolaryngology and ophthalmology, including face and body contouring, medical aesthetics and women's health.
Recurring news also covers GAAP and non-GAAP financial results, consumables and service revenue, regional performance in the United States and Europe, margin trends, investor-conference participation, board-reviewed strategic matters and capital allocation actions such as ordinary-share repurchase programs.
InMode Ltd. (Nasdaq: INMD) reported a record-breaking revenue of $121.2 million for Q3 2022, marking a 29% increase compared to Q3 2021. The company achieved a GAAP net income of $48.8 million or $0.58 per diluted share, up from $44.7 million or $0.52 in the previous year. Non-GAAP net income reached $56.6 million with a non-GAAP EPS of $0.66. Significant growth was seen in consumables and services, increasing 53% year-over-year to $13.9 million. Management also increased revenue targets for the EmpowerRF platform and plans global expansion.
InMode Ltd. (Nasdaq: INMD) anticipates record third-quarter revenue between $120.5 million and $120.9 million, alongside a projected non-GAAP gross margin of 84% to 85% and earnings per diluted share ranging from $0.64 to $0.65. The company has also raised its full-year 2022 revenue guidance to between $445 million and $450 million. A conference call to discuss these results is scheduled for October 27, 2022, at 8:30 a.m. ET.
On September 29, 2022, InMode Ltd. (Nasdaq: INMD) announced actress Eva Longoria as its Global Brand Ambassador. Longoria, known for her work on Desperate Housewives and her philanthropic efforts, will promote InMode's innovative medical technologies. She has personally utilized InMode’s EvolveX Transform and Morpheus8 Body treatments to address post-pregnancy body changes, emphasizing their effectiveness. InMode develops and markets cutting-edge devices leveraging radiofrequency technology across multiple medical fields, striving to enhance surgical procedures and existing treatments.
InMode Ltd. (Nasdaq: INMD) announced that CFO Yair Malca will present at the Baird 2022 Global Healthcare Conference on Sept. 13, 2022, at 1:25 pm Eastern Time at the InterContinental New York Barclay hotel. The presentation will be webcast on InMode's Investor Relations website. Malca will also hold one-on-one investor meetings on Sept. 13 and Sept. 14. InMode specializes in innovative medical technologies, focusing on minimally invasive RF technologies applicable in various medical fields.
InMode Ltd. (NASDAQ: INMD), a leader in innovative medical technologies, announced participation in the 7th Annual Needham Virtual Med Tech & Diagnostics Conference on August 16, 2022. Senior management, including Chairman and CEO Moshe Mizrahy and CFO Yair Malca, will engage in one-on-one meetings with investors that day. Interested parties can schedule meetings via their Needham representatives. InMode develops cutting-edge devices using radiofrequency technology for various medical fields, emphasizing minimally invasive surgical solutions.
InMode Ltd. (Nasdaq: INMD) reported record revenues of $113.5 million for Q2 2022, marking a 30% increase year-over-year. The company's GAAP net income rose to $44.0 million, with earnings per diluted share at $0.52. Non-GAAP net income reached $50.4 million, translating to $0.59 per diluted share. The company expects 2022 revenues of $425 million to $435 million and a non-GAAP gross margin between 83% and 85%. InMode also received Health Canada's endorsement for its EmpowerRF platform.
InMode Ltd. (NASDAQ: INMD) announced that CFO Yair Malca will present at the Canaccord 42nd Annual Growth Conference on August 11, 2022, at 3:30 PM ET, in Boston. The presentation will be available via webcast on the company's Investor Relations website. Malca is also scheduled for one-on-one meetings with investors on August 10 and August 11. InMode specializes in innovative medical technologies, focusing on minimally invasive RF procedures in various medical fields.
InMode Ltd. (INMD) announced expectations for record financial results in Q2 2022, forecasting revenue between $113.0 million to $113.3 million. The company anticipates a non-GAAP earnings per diluted share of $0.57 to $0.58. Additionally, InMode raised its full-year revenue guidance to a range of $425 million to $435 million, up from a previous range of $415 million to $425 million. The company attributes this growth to strong demand for its medical technologies in aesthetic surgery.
InMode Ltd. (Nasdaq: INMD) has launched the EmpowerRF Women's Wellness technology in Canada after receiving certification from Health Canada. This advancement aims to improve urinary incontinence symptoms (SUI) and builds upon existing licenses for Genitourinary Syndrome of Menopause (GSM) and chronic pelvic pain. The EmpowerRF platform offers advanced therapies, including intravaginal electrical muscle stimulation and bipolar radiofrequency. InMode emphasizes its commitment to enhancing women's health through effective, minimally invasive solutions. This initiative reflects a strategic milestone for InMode in the global healthcare market.
InMode Ltd. (Nasdaq: INMD), a prominent global provider of innovative medical technologies, announced participation in the UBS Healthcare One-on-One Virtual Day on June 1, 2022. CEO Moshe Mizrahy and CFO Yair Malca will represent the company. Interested parties can schedule meetings through their UBS representative or by contacting Miri Segal at msegal@ms-ir.com. InMode specializes in medical devices using radiofrequency technology, serving various medical fields including plastic surgery and dermatology.